Please provide your email address to receive an email when new articles are posted on . KidneyIntelX is a prognostic test that incorporates machine learning and predictive biomarkers. Clinical ...

On Thursday, Telo Genomics Corp (OTC:TDSGF) announced that the manuscript “Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma” was accepted for ...

SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that its Prolaris prostate cancer ...

Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Telo Genomics Corp. (TELO:CA) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology ...

Telo Genomics Corp (TSE:TELO) has released an update. Telo Genomics Corp has revealed promising results for its TeloViewSMM prognostic test, which outperformed existing models in identifying high and ...

BRAINBox Solutions today provided an update on the clinical, development, and corporate progress in its BRAINBox TBI diagnostic/prognostic test program. The BRAINBox tests for concussion (also known ...

A report outlining Almac Diagnostic’s new prognostic test to determine the risk of colon cancer recurrence was published in the online version of the Journal of Clinical Oncology. The test included 73 ...

VANCOUVER, Washington, June 19, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 ...

DiaCarta, Inc. ("DiaCarta"), a pioneer in molecular diagnostic test development for cancer and infectious diseases, based in California, today announced that it has established a strategic ...

Managing the invisible: Treatment approaches after pathological complete response (pCR) to neoadjuvant chemotherapy in oral cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I ...